

JMB

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Display Date	1-25-99
Publication Date	1-26-99
Certifier	J. J. Wind

Food and Drug Administration

Pharmacy Compounding Advisory Committee Meeting; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an amendment to the notice of a meeting of the Pharmacy Compounding Advisory Committee which is scheduled for February 4 and 5, 1999. This meeting was announced in the **Federal Register** of January 6, 1999 (64 FR 886). The amendment is being made to reflect a change in the *Procedure* portion of the meeting notice. There are no other changes. This amendment will be announced at the beginning of the open portion of the meeting.


FOR FURTHER INFORMATION CONTACT: Igor Cerny or Tony Slater, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, or FDA Advisory Committee Information Line, 1-800-741-8183 (301-443-0572 in the Washington, DC area), code 12440.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of January 6, 1999 (64 FR 886), FDA announced that a meeting of the Pharmacy Compounding Advisory Committee would be held on February 4 and 5, 1999. This amendment is being made to reschedule the time allotted for oral presentations from the public.

On page 887, in the first column, the *Procedure* portion of this meeting notice is amended to read as follows:

Procedure: Interested persons may present data, information or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by January 29, 1999. Oral presentations from the public will be scheduled on February 4, 1999,

between approximately 11 a.m. and 12 m. for: Mild silver protein, 4-aminopyridine, and 3,4-diaminopyridine, and between approximately 3 p.m. and 4 p.m. for: Hydrazine; and on February 5, 1999, between approximately 10 a.m. and 11 a.m. for: Dinitrochlorobenzene, diphenylcyclopropanone, and squaric acid dibutyl ester, and between approximately 3 p.m. and 4 p.m. for: Pentylenetetrazole, cyclandelate, and betahistine dihydrochloride. Time allotted for each presentation may be limited. Those desiring to make a formal oral presentation should notify the contact person before January 29, 1999, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.



Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app.

2).

Dated: January 20, 1999

ma

Michael A. Friedman
Deputy Commissioner for Operations

[FR Doc. 99-???? Filed ??-??-99; 8:45 am]

BILLING CODE 4160-01-F

CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL

Jan Windsor